News
Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...
An addition to a Columbus factory is part of a planned $1B U.S. expansion for Central Ohio's second-largest manufacturer.
12h
Medpage Today on MSNThis Dietary Pattern Is Linked With Lower Crohn's Disease RiskIn a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...
The (Raleigh) News & Observer on MSN1d
Future jet, big data center, more pharma: NC’s top 2025 jobs announcements (so far)Halfway through the year, these companies have pledged to hire the most workers in North Carolina. One is a record setter.
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...
StockStory.org on MSN5d
5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallAmgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...
In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...
Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.
Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...
US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results